Cohort (reference) | Study population | N | Region/country | Primary screening method(s) |
---|---|---|---|---|
Prospective patient screening studies | ||||
 Genetic screening | ||||
  Bauer et al. 2013 [31] | Adults with neurological/psych. Symptoms | 250 | EU and US | NPC1/NPC2 sequencinga, gene dosage analysis |
  Schicks et al. 2013 [32] | Adults with ataxia, EOCD and suspected recessive disease | 24 | Germany | NPC1/NPC2 sequencinga |
  Zech et al. 2013 [36] | Adults with PD, FTD or PSP | 790 | Germany | HRM followed by NPC1/NPC2 sequencinga |
  Nanetti et al. 2017 [33] | Adults with suspected HD | 18 | Italy | NPC1/NPC2 sequencinga |
  Topcu et al. 2017 [34] | Family members of NPC1/NPC2 probands | 510 | Turkey | NPC1/NPC2 sequencinga |
  Cupidi et al. 2017 [35] | Adults with early-onset ‘dementia-plus’ | 50 | Italy | NPC1/NPC2 sequencinga, gene dosage analysis |
  Synofzik et al. 2015 [27] | Adolescents/adults with unexplained EOA | 96 | Germany | NPC1/NPC2 (NGS gene panelb) |
  Marelli et al. 2016 [40] | Adolescents/adults with probable EOA | 33 | France | NPC1/NPC2 (NGS gene panel) |
  Pyle et al. 2015 [41] | Adult patients with inherited and sporadic ataxias | 35 | UK | NPC1/NPC2 sequencing (WES) |
  McKay et al. 2014 [42] | Infants with jaundice/cholestasis | 228 | UK | NPC1/NPC2 sequencing (WES) |
  Herbst et al. 2015 [43] | Infants with jaundice/cholestasis | 6 | Germany | NPC1/NPC2 sequencing (NGS gene panel) |
  Mavridou et al. 2014 [70] | Family members of NP-C patients | 153 | Greece | NPC1/NPC2 sequencinga, RFLP analysis |
  Wassif et al. 2016 [14] | Subjects from 4 WES sequencing projects | 17,754c | International | Historical WES + WES from public databases |
 Blood biomarker screening | ||||
  Reunert et al. 2016 [44] | Patients with suspected NP-C | 1800 | Germany | Oxysterol level (C-triol) |
  Ribas et al. 2016 [45] | Patients with suspected NP-C | 122 | Brazil | Oxysterol level (C-triol), ChT |
  Zhang et al. 2014 [46] | Children/adults with cholestasis, HSL or psychomotor regression/retardation | 302 | China | Oxysterol level (7-KC) |
  De Castro et al. 2017 [47] | Patients with suspected NP-C | 236 | Spain | ChT, CCL18/PARC, NPC1/NPC2 sequencinga |
  Sheth et al. 2014 [48] | Children with possible LSDs | 1110 | India, Sri Lanka, Afghanistan | Urine GAGs, plasma ChT, enzyme activity |
Studies based on archived (biobank) samples | ||||
 Cebolla et al. 2015 [50] | Patients with NP-C | 97 | Spain | Oxysterol level (7-KC) |
Studies based on patient file and clinical chart review | ||||
 Yerushalmi et al. 2002 [51] | Neonates with jaundice/cholestasis | 40 | US | Medical chart review |
 Hegarty et al. 2015 [52] | Children with acute liver failure | 127 | UK | Clinical, laboratory, and outcome analysis |
 Verity et al. 2010 [53] | Children with early cognitive impairment | 2636 | UK | Clinical case surveillance |
 Winstone et al. 2017 [54] | Children with intellectual and neurological deterioration | 3979 | UK | Clinical case surveillance |
 Corry 2014 [55] | Ethnic subjects with suspected autosomal recessive conditions | 13,000 | UK | Clinical case surveillance |
Studies based on newborn screening | ||||
 Pinto et al. 2004 [60] | Antenatal patients with suspected LSDs | 353 | Portugal | NPC1/NPC2 sequencinga |
 Polo et al. 2016 [61] | Neonates with cholestasis | 7 | Italy | Oxysterols (7-KC, C-triol) |